ReviewEndocrine pathology2007
Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors.
Review in Endocrine pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 77 citations in OpenAlex.
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Development of gastric mucosa-associated microbiota in autoimmune gastritis with neuroendocrine tumors.Journal of gastroenterology · 2025Article
- Quantitative characterization of duodenal gastrinoma autofluorescence using multiphoton microscopy.Lasers in surgery and medicine · 2023Article
- Review
- Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador.Healthcare (Basel, Switzerland) · 2022Article
- Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours.World journal of clinical cases · 2021Review
- A Novel Case of Carcinoid Tumor in a Pediatric Patient With Short Bowel Syndrome Secondary to Gastroschisis.JPGN reports · 2020Article
- Role of an active reserve stem cell subset of enteroendocrine cells in intestinal stem cell dynamics and the genesis of small intestinal neuroendocrine tumors.American journal of physiology. Gastrointestinal and liver physiology · 2020Review
- [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].Der Pathologe · 2019Article
- A primary hepatic gastrinoma accompanied by hyperplasia of multi-nodular Brunner's glands.Surgical case reports · 2017Article
- Elusive liver factor that causes pancreatic α cell hyperplasia: A review of literature.World journal of gastrointestinal pathophysiology · 2015Review
- Colorectal microcarcinoids in association with long-term exposure to urinary content: a case report and review of the literature.Case reports in pathology · 2015Article
- Zollinger-Ellison syndrome: recent advances and controversies.Current opinion in gastroenterology · 2013Review
- Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.Chinese journal of cancer · 2013Review
- Gastric neuroendocrine cell hyperplasia and type 1 tumours occurring within gastric hyperplastic polyps.Virchows Archiv : an international journal of pathology · 2012Article
- Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors.World journal of surgery · 2012Article
- Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.World journal of gastroenterology · 2011Article
- Pathologic pancreatic endocrine cell hyperplasia.World journal of gastroenterology · 2011Review
- Article
- Recent standardization of treatment strategy for pancreatic neuroendocrine tumors.World journal of gastroenterology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review focuses on precursor lesions of gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs). There are three conditions that are associated with hyperplastic changes in endocrine cells preceding GEP-NETs: autoimmune chronic atrophic gastritis or multiple endocrine neoplasia type 1 (MEN1) with gastric enterochromaffin-like (ECL) cell hyperplasia; MEN1 with gastrin and somatostatin cell hyperplasia in the duodenum and glucagon cell hyperplasia in the islets of the pancreas; and inflammatory bowel disease with endocrine cell hyperplasia in the colon. In gastric ECL cell hyperplasia, it is assumed that hypergastrinemia promotes the growth of the ECL cells of the corpus mucosa and leads to hyperplasia and neoplasia. In the duodenum and the pancreas, the MEN1-associated germline mutation of the menin gene obviously causes hyperplasia of the gastrin and somatostatin cells (duodenum) and the glucagon cells (pancreas), resulting in multifocal development of tumors. These tumors show allelic deletion of the MEN1 gene, whereas the precursor lesions retain their heterozygosity. The endocrine cell hyperplasia in the colon described in inflammatory bowel disease has neither a genetic nor a definite hormonal background.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.